

The stages of PASI

PASI 50

50% reduction in PASI score – an acceptable measure of efficacy for secondary endpoints in psoriasis clinical trials¹

PASI 75

75% reduction in PASI score – standard efficacy measure used in most psoriasis clinical studies¹

PASI 90

90% reduction in PASI score (almost clear skin)

PASI 100

Completely clear skin

PASI 90 AND 100
ARE CONSIDERED
THE MOST ROBUST
PRIMARY ENDPOINT
MEASURES
FOR EVALUATING
SKIN CLEARANCE¹



BASELINE
(Week 0)



PASI 50
(Achieved)



PASI 75
(Achieved)



PASI 90
(Achieved)

REFERENCE

1. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf Published November 2004. Accessed January 2015.

The stages of PASI

PASI 50

50% reduction in PASI score – an acceptable measure of efficacy for secondary endpoints in psoriasis clinical trials¹

PASI 75

75% reduction in PASI score – standard efficacy measure used in most psoriasis clinical studies¹

PASI 90

90% reduction in PASI score (almost clear skin)

PASI 100

Completely clear skin

**PASI 90 AND 100
ARE CONSIDERED
THE MOST ROBUST
PRIMARY ENDPOINT
MEASURES
FOR EVALUATING
SKIN CLEARANCE¹**

REFERENCE

1. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf Published November 2004. Accessed January 2015.